Mednostics Program: GNSC said it will start its STRENGTH II (Statin Response Examined by Genetic HAP Markers) trial to link clinical response to Mevacor lovasta

Genaissance Pharmaceuticals Inc. (GNSC), New Haven, Conn.
Product: Mednostics Program
Business: Pharmacogenetics
Therapeutic category: Test
Target:

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE